October 11, 2018 (ACCESSWIRE via COMTEX) — HENDERSON, NV / ACCESSWIRE / October 11, 2018 / Cannabis and Biotech companies have been receiving increased attention from the street as of late. One particular company that has caught significant attention from the street is none other than PPCB (Propanc Biopharma, Inc.). PPCB based on Wednesday’s closing price, is up 2153% from its low on August 27th. PPCB also has a 52 week high of $0.77.
PPCB is a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors, such as pancreatic, ovarian and colorectal cancers. PPCB’s lead product PRP was granted FDA Orphan Drug Designation status for the treatment of pancreatic cancer. If this is your first time hearing about PPCB, start doing your own due diligence right away. Orphan Drug Designation qualifies the Company for seven-year FDA-administered market Orphan Drug Exclusivity (ODE), tax credits of up to 50% of R&D costs, potential for R&D grants, waived FDA fees, protocol assistance and possible clinical trial tax incentives if conducted in the U.S. PPCB has some very exciting events on the horizon.
Biotechs and cannabis companies to watch include: Propanc Biopharma, Inc. (PPCB), TherapeuticsMD, Inc. TXMD, -3.04% Aurora Cannabis, Inc. (otcqx:ACBFF), Cronos Group, Inc. (CRON), and Trevena, Inc. TRVN, -7.06%
News Hub Live- HIDE PLAYER
Your browser does not support HTML5 video.
0:00 / 0:00
Your browser does not support the audio tag.
Click For Sound
Propanc Biopharma, Inc. (PPCB)
Market Cap: $15.49M Share Price: $0.084
Propanc Biopharma, Inc. (PPCB), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, just announced initiation of European (EP) validation of its lead patent in most major commercial markets in Europe. EP validation is the process of converting a single granted European patent application into a national patent in one or more contracting member and extension states of the European Patent Convention.
The Company’s lead patent, which describes a pharmaceutical composition for treating cancer, is currently undergoing validation in 14 European countries – Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Turkey and the United Kingdom. Once validated, the Company will have the rights associated with a granted patent in each of these 14 European countries.
Market Cap: $1.27B, Current share price: $5.41
TherapeuticsMD, Inc. is a women’s health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands.
Aurora Cannabis (ACBFF)
Market Cap: $9.67B Share Price: $10.046
Aurora Cannabis Inc. (ACBFF) announced it, and its wholly-owned subsidiary MedReleaf, have entered into additional supply arrangements with a number of provinces across Canada to supply a broad range of dried flower and higher margin products, such as pre-rolls, oils and capsules. In addition to supplying adult-consumer use markets in British Columbia , Alberta , Ontario , Quebec and Nova Scotia , the Company is pleased to advise of arrangements with Yukon , Manitoba , Prince Edward Island and Newfoundland and Labrador . The Aurora and MedReleaf brands are expected to have a strong presence across Canada , positioning the Company well for rapid growth in the upcoming adult use market.
Cronos Group, Inc. (CRON)
Market Cap: $2.04B Share Price: $11.56
Earlier this month Cronos announced a partnership with Ginkgo Bioworks. The landmark partnership is to produce cultured cannabinoids. Ginkgo Bioworks, using its platform technology for organism design and development, will complement Cronos Group’s technologies for producing a full spectrum of cannabinoids. Cronos Group has agreed to issue a specific number of common shares in tranches subject to Ginkgo’s achievement of certain production milestones.
Trevina, Inc. (TRVN)
Market Cap: $264M Share Price: $3.47
Trevena, Inc. (TRVN), recently announced the completion of its previously announced leadership transition with Carrie L. Bourdow, formerly the Company’s Executive Vice President and Chief Operating Officer, assuming the role of President and Chief Executive Officer. In connection with this transition, Ms. Bourdow also was appointed to the Company’s Board of Directors. Maxine Gowen, Ph.D., the Company’s founding President and CEO, has retired, and remains a member of the Board of Directors. Trevena also announced today the appointment of Scott Braunstein, M.D., to its Board of Directors.
Important Disclaimer, Please Read:
The securities, investments, and industries referenced and impacted in the attached content, are risky investments, that can result in significant or entire loss. This article is not advice in making any speculative investment decision.
The attached content may include predictions, estimates or other information that might be considered forward-looking. While such forward-looking statements represent best judgment on what the future holds, at the time of first publishing, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on any forward-looking statements, that may be found in the attached content, as they only reflect as of the date of first publishing. Please keep in mind that authors, producers, disseminators are not obligated to revise or publicly release the results of any revision to any forward-looking statement, that may be found in the attached content, in light of new information or future events.
Regal Consulting LLC is hired by certain companies to increase awareness and disseminate material public information regarding the paying company. PPCB has paid, and continues to pay Regal to disseminate truthful and potentially material information regarding PPCB.
Regal Consulting LLC is not registered with FINRA or any other financial or securities regulatory authority, and does not provide investment advice. The attached content is not investment advice. Regal Consulting LLC is not a broker dealer.
Before making investment decisions, everyone, including viewers of this content, should seek advice and perform deep and thorough research.
Regal Consulting, LLC. may buy or sell additional shares of any company named, referenced, or impacted by information in the attached content, on the open market at any time, including before, during or after the publishing of the content. The amount of stock Regal may own in PPCB can be found updated here: http://www.regalconsultingllc.com/disclaimer/.
Micro-Cap Speculators Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and eighty-six thousand four hundred dollars total by Regal Consulting. LLC, for news commentary articles for PPCB. PPCB and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communications, LLC. and the hiring party Regal Consulting, LLC. may buy or sell additional shares of PPCB in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: ACR Communication, LLC
Copyright 2018 ACCESSWIRE